Histone deacetylase inhibitors in APL and beyond.

Petrie, Kevin, Prodromou, N and Zelent, A (2007) Histone deacetylase inhibitors in APL and beyond. Current topics in microbiology and immunology, 313. pp. 157-203. ISSN 0070-217X

[img] PDF
2007 Histone Deacetylase Inhibitors in APL and Beyond.pdf - Accepted Version
Restricted to Repository staff only

Download (2MB)

Search Google Scholar


In recent years the study of chemical modifications to chromatin and their effects on cellular processes has become increasingly important in the field of cancer research. Disruptions to the normal epigenetic pattern of the cell can serve as biomarkers and are important determinants of cancer progression. Accordingly, drugs that inhibit the enzymes responsible for modulating these epigenetic markers, in particular histone deacetylases, are the focus of intense research and development. In this chapter we provide an overview of class I and II histone deacetylases as well as a guide to the diverse types of histone deacetylase inhibitors and their activities in the context of APL. We also discuss the rationale for the use of histone deacetylase inhibitors in combination therapy for the treatment of cancer and the current status of clinical trials.

Item Type: Article
Subjects: Sciences > Biomedical Sciences
Sciences > Health Sciences
Divisions: Faculty of Health Sciences and Wellbeing > School of Medicine
Depositing User: Kevin Petrie
Date Deposited: 18 Aug 2020 11:18
Last Modified: 30 Sep 2020 10:48
URI: http://sure.sunderland.ac.uk/id/eprint/12426
ORCID for Kevin Petrie: ORCID iD orcid.org/0000-0002-9805-9152

Actions (login required)

View Item View Item


Downloads per month over past year